These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 10744007)

  • 1. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon.
    Frick RW
    Angiology; 2000 Mar; 51(3):197-205. PubMed ID: 10744007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From symptoms to leg edema: efficacy of Daflon 500 mg.
    Nicolaides AN
    Angiology; 2003; 54 Suppl 1():S33-44. PubMed ID: 12934755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency.
    Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Vinciguerra G; Ricci A; Di Renzo A; Ruffini I; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cornelli U; Hosoi M; Cacchio M
    Angiology; 2006; 57(2):131-8. PubMed ID: 16518519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial.
    Belcaro G; Cesarone MR; Bavera P; Ricci A; Renton S; Leon M; Ippolito E; Dugall M; Acerbi G
    J Cardiovasc Pharmacol Ther; 2002 Jul; 7(3):139-45. PubMed ID: 12232562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study.
    Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Di Renzo A; Vinciguerra G; Ricci A; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cacchio M
    Angiology; 2005; 56(1):1-8. PubMed ID: 15678250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg.
    Bergan JJ
    Angiology; 2005; 56 Suppl 1():S21-4. PubMed ID: 16193222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency.
    Ramelet AA
    Angiology; 2001 Aug; 52 Suppl 1():S49-56. PubMed ID: 11510597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency.
    Katsenis K
    Curr Vasc Pharmacol; 2005 Jan; 3(1):1-9. PubMed ID: 15641940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy.
    Ting AC; Cheng SW; Wu LL; Cheung GC
    Vasc Surg; 2001; 35(6):443-7. PubMed ID: 16222383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
    Struckmann JR; Nicolaides AN
    Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
    Lyseng-Williamson KA; Perry CM
    Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
    Geroulakos G; Nicolaides AN
    Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
    Tsouderos Y
    Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological agents in the treatment of venous disease: an update of the available evidence.
    Gohel MS; Davies AH
    Curr Vasc Pharmacol; 2009 Jul; 7(3):303-8. PubMed ID: 19601855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of micronized purified flavonoid fraction: an overview.
    Struckmann JR
    J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins.
    Raffetto JD; Khalil RA
    J Vasc Surg; 2011 Aug; 54(2):489-96. PubMed ID: 21498026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
    Amato C
    Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions.
    Perrin M; Ramelet AA
    Eur J Vasc Endovasc Surg; 2011 Jan; 41(1):117-25. PubMed ID: 21126890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg.
    Le Dévéhat C; Khodabandehlou T; Vimeux M; Kempf C
    Int J Microcirc Clin Exp; 1997; 17 Suppl 1():27-33. PubMed ID: 9477042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg.
    Bergan JJ; Schmid-Schönbein GW; Takase S
    Angiology; 2001 Aug; 52 Suppl 1():S43-7. PubMed ID: 11510596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.